Rep. Thomas H. Kean, Jr. Sells Off Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• Representative Thomas H. Kean, Jr. sold between $15,001 and $50,000 in shares of Johnson & Johnson (NYSE:JNJ) on July 31st, as disclosed on August 20th.
• Johnson & Johnson reported a quarterly earnings per share (EPS) of $2.77, exceeding analysts' expectations, with a revenue of $23.74 billion, up 5.8% year-over-year.
• The company will pay a quarterly dividend of $1.30 on September 9th, with a 2.9% yield and a dividend payout ratio of 55.61%.

Representative Thomas H. Kean, Jr. (R-New Jersey) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on August 20th, the Representative disclosed that they had sold between $15,001 and $50,000 in Johnson & Johnson stock on July 31st. The trade occurred in the Representative's "STATE STREET BANK & TRUST CO." account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Stryker NYSE: SYK on 7/31/2025.
• Purchased $15,001 - $50,000 in shares of Check Point Software Technologies NASDAQ: CHKP on 7/29/2025.
• Sold $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 7/29/2025.
• Purchased $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 7/21/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 6/30/2025.
• Sold $15,001 - $50,000 in shares of Stryker NYSE: SYK on 6/26/2025.
• Sold $1,001 - $15,000 in shares of WESCO International NYSE: WCC on 6/23/2025.
• Purchased $1,001 - $15,000 in shares of Danaher NYSE: DHR on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of AON NYSE: AON on 5/27/2025.

Johnson & Johnson Stock Up 0.0%

Shares of NYSE JNJ opened at $178.8990 on Friday. The firm has a fifty day simple moving average of $163.04 and a two-hundred day simple moving average of $159.05. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $180.61. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $430.85 billion, a PE ratio of 19.13, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 earnings per share. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is 55.61%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on JNJ shares. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Morgan Stanley upped their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Bank of America raised their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Guggenheim reaffirmed a "neutral" rating and issued a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Barclays lifted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Clarion Wealth Managment Partners LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $1,196,000. Monarch Capital Management Inc. raised its stake in Johnson & Johnson by 0.7% during the 2nd quarter. Monarch Capital Management Inc. now owns 62,282 shares of the company's stock valued at $9,514,000 after buying an additional 426 shares during the last quarter. North Dallas Bank & Trust Co. bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at $2,274,000. Coppell Advisory Solutions LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth $1,947,000. Finally, Marex Group plc bought a new stake in shares of Johnson & Johnson in the second quarter worth $634,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.